About this trial
The aim of this study is to evaluate the prevalence of synovitis in adult patients with haemophilia A.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Participants (≥ 18 years old) suffering from moderate or severe haemophilia A, also with inhibitor or joint replacement
Complete documentation of hemophilia severity, treatment history (past 12 months), and bleeding events (past 12 months), inhibitor status (at time of enrollment and in past medical history)
Submitted written consent to participate in the study
Disqualifiers
Patients suffering from other bleeding disorders conflicting with the research question
Patients in clinical studies with investigational drugs
Trial population
Adult patients (≥ 18 years of age) suffering from moderate (FVIII 1-5 %) or severe (FVIII \<1 %) haemophilia A.
Trial design
Cohort
Prospective
Treatments tested in this trial
Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US); Haemophilia joint health score (HJHS)
Diagnostic testEach subject is examined for the presence of synovitis using the aforementioned diagnostics.
Treatment groups
Trial outcomes
Primary outcomes
Haemophilia early arthropathy detection with ultrasound (HEAD-US)
HEAD-US protocol examines both elbow, knee and ankle joints sonographically and assesses the presence of synovitis or joint damage from 0-8 points per joint according to Martinoli et al. 2013. A "total score" of 0 to 48 points is achievable. A higher score means a worse joint status.
Secondary outcomes
The Hemophilia Joint Health Score version 2.1 (HJHS)
Clinical joint examination according to De la Corte-Rodriguez et al. 2020. HJHS protocol examines both elbow, knee and ankle joints using a goniometer for range of motion and axial alignment (0-3 points), pain numerical rating scale (0-10 points), swelling (0-3 points), crepitation (0-2 points) and gait abnormalities (0-4 points). A "total score" of 0 to 124 points is achievable. A higher score means a worse joint status.
PROMIS-29 Questionaire
Patient-reported outcomes are surveyed using short questionnaires with a stable number of items from seven PROMIS sub scales ("depression", "anxiety", "physical functioning", "impairment due to pain", "fatigue", "sleep impairment", "participation in social roles" and "activities"). The measures use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. For the sub scales "participation in social roles and activities" and "physical functioning", a high score is interpreted as a good result and for the sub scales "anxiety", "depression", "fatigue", "impairment due to pain", and "sleep impairment" a low score is a good result.
Haemophilia Activities List (HAL)
to evaluate to subjective physical performance. A higher scores represent a better functional status. Scores can be calculated for each of ten domains of the HAL and a sum score ("Lying / sitting / kneeling / standing" (8-48 Points), "Functions of the legs" (9-54 Points), "Functions of the arms" (4-24 Points), "Use of transportation" (3-18 Points), "Self care" (5-30 Points), "Household tasks" (6-36 Points), "Leisure activities and sports" (7-42 Points), "Upper Extremity Activities" (9-54 Points), "Basic Lower Extremity Activities" (6-36 Points), "Complex Lower Extremity Activities" (9-54 Points), and "Sum score" (42-252 Points).
Other outcomes
Baseline Characteristics
1. General anamnesis questionnaire (diseases, pain medication, surgeries, haemophilia related clinical data, date of birth, weight in kilograms, hight in centimeters. 2. Haemophilia treatment past twelve months (on demand/prophylaxis/non-factor therapy/EHL or SHL therapy) 3. Bleeding events past twelve months (traumatic or spontaneous)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital, Bonn
Lead sponsor
Swedish Orphan Biovitrum
Collaborator